Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies

Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care remains complex. Rapidly evolving clinical evidence, the growing role of biomarker-driven therapies, and the need to proactively manage treatment-related toxicities all require ongoing clinical integration to support patient safety and continuity of care. Concurrently, inequities persist in access to molecular testing, novel therapies, and clinical trials, underscoring the need for refined interprofessional, patient-centered approaches that promote equitable access, reduce disparities, and enhance patient education to optimize outcomes.

In this CE Concepts recorded webcast, expert faculty will review recent developments in the management of advanced or recurrent EC, with a focus on applying emerging clinical evidence, integrating biomarker-driven therapies, and addressing treatment-related toxicities. This program will further explore strategies to enhance interprofessional collaboration, support equitable access to molecular testing and novel therapies, and strengthen patient-centered education to optimize care delivery.

At the conclusion of this activity, learners will be able to better:

• Interpret clinical evidence on new and emerging therapies to define their role in current and evolving treatment paradigms for advanced or recurrent endometrial cancer
• Manage treatment-related adverse effects using evidence-based strategies to maintain treatment continuity and ensure patient safety
• Implement multidisciplinary and patient-centered strategies to overcome access barriers, address disparities, and incorporate patient education and patient-reported outcomes into the care of patients with advanced or recurrent endometrial cancer

This activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Health care professionals involved in the treatment, care, and support of patients with advanced or recurrent endometrial cancer, including gynecologic oncologists, medical oncologists (community and academic), pathologists, nurse practitioners (NPs), physician associates (PAs), oncology nurses, pharmacists, and other members of the multidisciplinary care team

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Moore reports the following financial relationships:

Advisory Board: Aadi Bioscience; AbbVie Inc.; AstraZeneca; BeOne Medicines; BioNTech; Caris Life Sciences; Corcept Therapeutics, Inc; Daiichi Sankyo; DualityBio; GSK; Immunogen; Iovance Biotherapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc; Mersana Therapeutics Inc; Regeneron Pharmaceuticals Inc.; Schrodinger; Takeda Pharmaceuticals; Verastem, Inc.; Whitehawk Therapeutics, Inc.; Zentalis Pharmaceuticals; and Zymeworks Inc.

Research Support: Accent Therapeutics; Advaxis, Inc; Allarity Therapeutics, Inc.; AstraZeneca; Daiichi-Sankyo; GSK; Schrodinger; and Verastem, Inc.

Other financial or material support: GOG Partners Associate Director

Ms. Shaver reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Taylor Wallace (Planning Committee)
Kashemi D. Rorie, PhD (Planning Committee)
Felicia Oyedepo, MD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.